Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

623
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
623
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

786
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
786

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Re-evaluation of "Peptic" duodenitis: A review of 622 consecutive duodenal biopsies.

Annals of diagnostic pathology·2026
Same author

KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53.

The Journal of biological chemistry·2026
Same author

Cholecystocolic fistula: a pictorial review.

Abdominal radiology (New York)·2026
Same author

A machine learning model of lamina propria fibrosis in eosinophilic esophagitis for prediction of fibrostenotic disease.

Journal of pathology informatics·2026
Same author

Spatial Conformation of Pancreatic Cancer Is Associated with Disease Recurrence after Curative-Intent Total Neoadjuvant Therapy.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jan 14, 2026

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

1.2K

Assessing Risk of Progression in Barrett's Esophagus Using a Mass-Spectrometry-Based Proteomic Panel.

Andrew Cannon1, Rofyda Elhalaby1, Igor Ban2

  • 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Clinical and Translational Gastroenterology
|October 24, 2025
PubMed
Summary

A new 8-protein panel accurately predicts esophageal adenocarcinoma progression in Barrett's esophagus patients. This proteomic test aids in selecting patients for surveillance and supports management decisions.

Keywords:
Barrett's esophagusmass spectrometryprogressionproteomicsrisk stratification

More Related Videos

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.9K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

817

Related Experiment Videos

Last Updated: Jan 14, 2026

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

1.2K
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.9K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

817

Area of Science:

  • Proteomics
  • Oncology
  • Gastroenterology

Background:

  • Esophageal adenocarcinoma (EAC) is a deadly cancer with Barrett's esophagus (BE) as a precursor.
  • Current endoscopic surveillance for BE has limitations in accuracy and invasiveness.
  • Predicting progression from BE to EAC is crucial for patient management.

Purpose of the Study:

  • To evaluate an 8-protein mass spectrometry panel for predicting progression in BE patients.
  • To assess the utility of a proteomic panel in identifying individuals at high risk for EAC development.

Main Methods:

  • Quantitative mass spectrometry was performed on microdissected tissue from 92 BE patients.
  • A logistic classifier was trained using Least Absolute Shrinkage and Selection Operator-regularized regression.
  • Model performance was evaluated using training and testing datasets.

Main Results:

  • The proteomic panel achieved 100% sensitivity and 39% specificity in predicting progression.
  • Area Under the Curve (AUC) values were 0.75 (overall) and 0.89 (test cohort).
  • The model significantly predicted time-to-progression (Hazard Ratio = 66.1, P = 0.00012).

Conclusions:

  • The 8-protein panel shows promise as a risk stratification tool for BE patients.
  • This proteomic test may improve the selection of patients for active surveillance.
  • The model's association with time-to-progression can aid in clinical decision-making for BE management.